logo-loader
viewFSD Pharma

Zachs Small-Cap Research initiates coverage on FSD Pharma with a comparable analysis valuation price target of $0.23

Zachs thinks FSD Pharma is well positioned to benefit from the legalization of cannabis in Canada, Germany, the rest of the Eurozone and the US

Cannabis plants
It noted that the firm’s first commercial crop of pharmaceutical-grade cannabis has been harvested at its Cobourg facility

Zachs Small-Cap Research has initiated coverage on FSD Pharma (CSE:HUGE) (OTCMKTS:FSDDF) with a comparable analysis valuation price target of $0.23 on the expectation that the stock will attain a second quartile P/B (price/book) ratio of 4.1.

FSD Pharma shares were trading at C$0.095 in early Toronto trade on Tuesday, and at $0.0769 on the OTC in New York.

In a note to clients, Zachs’ analysts Steven Ralston pointed out that FSD Pharma is a cannabis-platform company focused on the cultivation, processing and distribution of pharmaceutical-grade cannabis as well as the development of pharmaceutical and synthetic cannabinoid-based treatments for a variety of clinical indications.

READ: FSD Pharma launches private placement to raise up to US$5 million

He noted that the firm’s first commercial crop of pharmaceutical-grade cannabis has been harvested at its Cobourg facility and is being offered for direct sale through the company’s website via the fulfillment of prescriptions.

The analyst said: “Through strategic alliances, collaborative agreements and acquisitions, FSD is pursuing the development of FDA-approved medications for pain management, fibromyalgia, IBS and coronary artery disease.”

He sees near term catalysts for the stock as coming from general news flow on the management internal initiatives and external partnerships and is watching for:

  • Operating results of the online initiative at FVPharma.com;
  • Completion of capacity expansion at Cobourg facility;
  • Solarvest development of a proof of concept that that algae can express pharmaceutical-grade cannabinoids through biosynthesis;
  • Canntab Therapeutics start of manufacturing commercial batches of oil-filled gel capsules at FSD’s Cobourg facility;
  • Canntab Therapeutics’s XR tablet awaiting approval by Health Canada
  • The analysts also noted that the company is waiting results of clinical trials at:
  • SciCann Therapeutics for IBS
  • Prismic Pharmaceuticals for pain management and fibromyalgia

The company will also build awareness of the company and management’s strategy, Ralston added, by attending analyst conferences and industry forums, including the 11th Annual Biotech Showcase in San Francisco (January 7, 2019); Arcview Cannabis Investor Forum in Vancouver (April 25, 2019); 2019 BIO International Convention in Philadelphia ((June 4, 2019); and MJ Link Micro Investor Conference in NYC (June 25, 2019)

The Zachs’ analyst concluded that FSD Pharma is well positioned to benefit from the legalization of cannabis in Canada, Germany, the rest of the Eurozone and the United States.

Contact the author at [email protected]

Quick facts: FSD Pharma

Price: 10 CAD

CSE:HUGE
Market: CSE
Market Cap: $78.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

FSD Pharma CEO updates corporate moves, progress at hydroponic cannabis facility

FSD Pharma Inc (CSE:HUGE) (OTCQB: FSDDF) interim CEO Dr. Raza Bokhari updates Proactive Investors on the cannabis company's partners, management, and recent achievements. Bokhari says FSD is on track to transform its 25,000 sq. ft facility in Cobourg, Canada into the world’s largest...

on 20/2/19

2 min read